Literature DB >> 25588018

Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling.

Matthias Liechti1.   

Abstract

Novel psychoactive substances are newly used designer drugs ("internet drugs", "research chemicals", "legal highs") potentially posing similar health risks to classic illicit substances. Chemically, many novel psychoactive substances can be classified as phenethylamines, amphetamines, synthetic cathinones, piperazines, pipradrols/piperidines, aminoindanes benzofurans, and tryptamines. Pharmacologically, these substances interact with various monoaminergic targets. Typically, stimulants inhibit the transport of dopamine and noradrenaline (pipradrols, pyrovalerone cathinones) or induce the release of these monoamines (amphetamines and methamphetamine-like cathinones), entactogens predominantly enhance serotonin release (phenylpiperazines, aminoindanes, para-substituted amphetamines, and MDMA-like cathinones) similar to MDMA (ecstasy), and hallucinogens (tryptamines, hallucinogenic phenethylamines) are direct agonists at serotonergic 5-HT2A receptors. Synthetic cannabinoids are another group of novel substances which all act as agonists at the cannabinoid CB1 receptor similar to THC but are chemically diverse. In particular, the relative serotonergic vs dopaminergic activity (determined by the dopamine/serotonin transporter inhibition ratio in vitro) can be helpful to predict the desired psychotropic but also the toxic effects of novel substances as well as their potential for addiction. Although the use of novel psychoactive substances mostly produces minor or moderate poisonings, serious complications occur. Serotonergic drugs (entactogens and hallucinogens) are associated with acute serotonin syndrome, hyperthermia, seizures, and hyponatremia. Dopaminergic drugs are highly addictive and acute toxicity includes prolonged stimulation, insomnia, agitation, and psychosis. Agitation, anxiety, paranoia, hypertension, and rarely myocardial infarction and renal failure are seen with synthetic cannabinoids. Treatment is supportive.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25588018     DOI: 10.4414/smw.2015.14043

Source DB:  PubMed          Journal:  Swiss Med Wkly        ISSN: 0036-7672            Impact factor:   2.193


  54 in total

Review 1.  Synthetic cannabinoids 2015: An update for pediatricians in clinical practice.

Authors:  Daniel Castellanos; Leonard M Gralnik
Journal:  World J Clin Pediatr       Date:  2016-02-08

2.  Atypical dopamine efflux caused by 3,4-methylenedioxypyrovalerone (MDPV) via the human dopamine transporter.

Authors:  Aparna Shekar; Jenny I Aguilar; Greta Galli; Nicholas V Cozzi; Simon D Brandt; Arnold E Ruoho; Michael H Baumann; Heinrich J G Matthies; Aurelio Galli
Journal:  J Chem Neuroanat       Date:  2017-02-03       Impact factor: 3.052

3.  New drug controls and reduced hospital presentations due to novel psychoactive substances in Edinburgh.

Authors:  Janice Pettie; Allan Burt; Duleeka W Knipe; Hazel Torrance; Margaret Dow; Karen Osinski; Robert Greig; Diletta Sabatini; Kate Easterford; James Dear; Michael Eddleston
Journal:  Br J Clin Pharmacol       Date:  2018-07-20       Impact factor: 4.335

Review 4.  Clinical value of analytical testing in patients presenting with new psychoactive substances intoxication.

Authors:  Katharina Elisabeth Grafinger; Matthias E Liechti; Evangelia Liakoni
Journal:  Br J Clin Pharmacol       Date:  2019-12-17       Impact factor: 4.335

Review 5.  The Bridge Between Classical and "Synthetic"/Chemical Psychoses: Towards a Clinical, Psychopathological, and Therapeutic Perspective.

Authors:  Laura Orsolini; Stefania Chiappini; Duccio Papanti; Domenico De Berardis; John M Corkery; Fabrizio Schifano
Journal:  Front Psychiatry       Date:  2019-11-20       Impact factor: 4.157

6.  Metabolites of the ring-substituted stimulants MDMA, methylone and MDPV differentially affect human monoaminergic systems.

Authors:  Dino Luethi; Karolina E Kolaczynska; Melanie Walter; Masaki Suzuki; Kenner C Rice; Bruce E Blough; Marius C Hoener; Michael H Baumann; Matthias E Liechti
Journal:  J Psychopharmacol       Date:  2019-04-30       Impact factor: 4.153

7.  Pharmacological profile of novel psychoactive benzofurans.

Authors:  Anna Rickli; Simone Kopf; Marius C Hoener; Matthias E Liechti
Journal:  Br J Pharmacol       Date:  2015-04-24       Impact factor: 8.739

8.  Human Pharmacology of Mephedrone in Comparison with MDMA.

Authors:  Esther Papaseit; Clara Pérez-Mañá; Julián-Andrés Mateus; Mitona Pujadas; Francina Fonseca; Marta Torrens; Eulàlia Olesti; Rafael de la Torre; Magí Farré
Journal:  Neuropsychopharmacology       Date:  2016-05-20       Impact factor: 7.853

9.  Cytotoxic Activity of Pyrovalerone Derivatives, an Emerging Group of Psychostimulant Designer Cathinones.

Authors:  Jakub Wojcieszak; Dariusz Andrzejczak; Agata Woldan-Tambor; Jolanta B Zawilska
Journal:  Neurotox Res       Date:  2016-06-13       Impact factor: 3.911

10.  The clinical challenges of synthetic cathinones.

Authors:  Fabrizio Schifano; Flavia Napoletano; Davide Arillotta; Caroline Zangani; Liam Gilgar; Amira Guirguis; John Martin Corkery; Alessandro Vento
Journal:  Br J Clin Pharmacol       Date:  2020-02-03       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.